$ 49 / 10mg
999 in stock (can be backordered)
Selank Amidate is a synthetic heptapeptide analogue of the endogenous immunomodulator tuftsin, developed at the Institute of Molecular Genetics (Russian Academy of Sciences). Selank peptide is studied for its dual nootropic and immunomodulatory properties — a unique pharmacological profile that bridges cognitive neuroscience and immune-system research. The amidate modification enhances metabolic stability, providing extended activity in research models.
Selank peptide modulates GABA-A receptor allosteric sites, increases brain-derived neurotrophic factor (BDNF) expression, and influences serotonergic and dopaminergic transmission. On the immune side, it enhances IL-6 expression and modulates T-helper cell balance. This dual mechanism — anxiolytic/nootropic combined with immunomodulatory — distinguishes Selank from single-pathway compounds like benzodiazepines or conventional immune modulators.
Semax is Selank’s nootropic counterpart — an ACTH-fragment peptide focused on cognitive enhancement and neuroprotection. DSIP targets sleep and stress-hormone regulation, while Oxytocin provides a social-behavior angle on stress-response research.
Each vial contains Selank Amidate peptide manufactured in the USA under ISO-certified conditions. Verified to ≥99% purity by HPLC analysis, with endotoxin screening below 0.1 EU/mg. Certificate of Analysis (COA) available upon request. For laboratory research use only.
Lyophilized Selank Amidate peptide should be stored at -20°C in a sealed, desiccated container protected from light and moisture for maximum long-term stability. Reconstitute with bacteriostatic water and store the solution at 2–8°C, using all reconstituted material within 28 days. Prepare single-use aliquots at the time of reconstitution to avoid repeated freeze-thaw cycles that may compromise peptide integrity. Follow standard aseptic laboratory handling protocols for all preparation steps. This product is for laboratory research use only and is not intended for human consumption.
Selank was developed in the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences by the research team led by Dr. Nikolai Myasoedov, the same group responsible for Semax. The peptide was designed as a synthetic analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide, with three additional amino acids to enhance receptor binding and metabolic stability. Selank has been the subject of over 150 peer-reviewed publications in journals including Bulletin of Experimental Biology and Medicine, Journal of Psychopharmacology, and Regulatory Peptides. Research groups at Moscow State University, the Russian Academy of Medical Sciences, and the Institute of Gene Biology have extensively studied its dual anxiolytic and immunomodulatory mechanisms. Selank remains a uniquely positioned research compound at the intersection of neuroscience and immunology, offering a pharmacological profile not replicated by conventional single-target anxiolytics.
Selank acts through dual mechanisms — combining GABA-A receptor modulation for anxiolytic effects with immunomodulatory activity via IL-6 and T-helper cell balance. Unlike benzodiazepines that target only GABAergic pathways, Selank simultaneously influences both neurological and immune systems. This compound is supplied for laboratory research use only.
Each batch is manufactured in the USA under ISO-certified conditions and verified to ≥99% purity by HPLC analysis, with endotoxin levels confirmed below 0.1 EU/mg. A full Certificate of Analysis (COA) is available upon request to support research compliance and documentation.
Selank and Semax are frequently studied as complementary compounds in neuroscience research, as they target different but overlapping pathways — Selank via GABAergic and immune modulation, and Semax via BDNF and monoaminergic systems. Researchers investigating multi-target nootropic strategies often evaluate both peptides in parallel or combined protocols. Both products are intended for research use only.
